Biopharmaceutical Professional | Strategy | Leadership | Innovation | Growth | New Product & Commercial Development
IgG4-RD is a rare, systemic disease that is highly treatable if diagnosed early. That’s why it is so exciting to see it receive an ICD-10 code designation, which will help minimize time to diagnosis and treatment, thereby improving outcomes for patients. This is only the beginning of a hopeful future for those impacted by IgG4-RD. Read more from John Stone MD, MPH in HCPLive. https://lnkd.in/gjNgE5Qx
Congratulations on moving this important research forward!!
Michael Kearney
11mo
Congrats Andrew. Major!
R&D Strategy and Operations at Relay Therapeutics
11moAwesome to hear - congrats to the team on this major progress!